Analysis of a Phase II Study of Cabozantinib in mCRPC

July 15, 2014
Edwin M. Posadas, MD, FACP

Edwin M. Posadas, MD, FACP, medical director, Urologic Oncology Program, Cedars-Sinai’s Samuel Oschin Comprehensive Cancer Institute, discusses a translational phase II study of cabozantinib in men with metastatic castration-resistant prostate cancer (mCRPC) with visceral metastases with characterization of circulating tumor cells and large oncosomes.

Edwin M. Posadas, MD, FACP, medical director, Urologic Oncology Program, Cedars-Sinai’s Samuel Oschin Comprehensive Cancer Institute, discusses a translational phase II study of cabozantinib in men with metastatic castration-resistant prostate cancer (mCRPC) with visceral metastases with characterization of circulating tumor cells and large oncosomes.

Clinical Pearls:

  • The presence of visceral metastatses is a poor prognostic indicator for men with prostate cancer.
  • Seven of the 8 patients enrolled in the trial so far have experienced prolonged disease stability.
  • One patient with liver metastases saw a regression of his liver disease in 12 weeks of treatment.
  • Researchers of this trial are characterizing circulating tumor cells and large oncosomes in the hopes of one day eliminating the need for needle biopsies for men with prostate cancer.